Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F] LBT-999 PET vs [123I]-FP-CIT SPECT in Parkinson's Disease and Essential Tremor
NCT04265209Phase 3Completed
- Sponsor
- GE HealthCare
- Start
- Dec 2021
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of 18f-lbt-999 (2 arms), sponsored by GE HealthCare. Primary endpoint: Sensitivity and Specificity by Visual Analysis. Started Dec 2021; status: completed.
02
Drugs
18f-lbt-999
Beyond the preview
Go deeper on NCT04265209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04265209.